Advertisement

DNP - Der Neurologe & Psychiater

, Volume 19, Issue 2, pp 55–63 | Cite as

Work-up polyneuropathisches Syndrom

Polyneuropathien — was ist diagnostisch sinnvoll?

  • Christian Bischoff
Zertifizierte Fortbildung
  • 192 Downloads

Zusammenfassung

Der Begriff Polyneuropathie umfasst eine Vielzahl unterschiedlicher Erkrankungen und Erscheinungsformen. Diagnostik und ätiologische Zuordnung sind von enormer Bedeutung bei diesem Krankheitsbild mit hoher Prävalenz. Am Anfang stehen die Anamneseerhebung sowie die klinische Untersuchung. Zusatzuntersuchungen dienen dazu, eine weitere Einordnung des polyneuropathischen Syndroms vorzunehmen mit dem Ziel, eine Ursache zu finden.

Literatur

  1. 1.
    Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 2016; 87(18):1892–8CrossRefGoogle Scholar
  2. 2.
    Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016; 31:5–20CrossRefGoogle Scholar
  3. 3.
    Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. J. Neurol 2016; 263:1903–10CrossRefGoogle Scholar
  4. 4.
    Morrison B, Chaudry V. Medication, toxic and vitamin-related neuropathy. Continuum 2012; 18:139–60PubMedGoogle Scholar
  5. 5.
    Windebank AJ, Grisold W. Chemotherapy induced neuropathy. J Peripher Nerv Syst 2008; 13:27–46CrossRefGoogle Scholar
  6. 6.
    Kastenbauer T, Sauseng S, Brath H, Abrahamian H, Irsigler K. The value of the Rydel-Seiffert tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med 2004; 21:563–7CrossRefGoogle Scholar
  7. 7.
    England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64(2):199–207CrossRefGoogle Scholar
  8. 8.
    Watson JC, Dyck PBJ. Peripheral neuropathy: A practical approach to diagnosis and symptom management. Mayo Clin Proc 2015; 90:940–51CrossRefGoogle Scholar
  9. 9.
    Devigili G et al. The diagnostic criteria for small fiber neuropathy: from symptoms to neuropathology. Brain 2008; 131:1912–25CrossRefGoogle Scholar
  10. 10.
    Bromberg M. An electrodiagnostic approach to the evaluation of peripheral neuropathies. Phys Med Rehabil Clin N Am 2013; 24:153–68CrossRefGoogle Scholar
  11. 11.
    Bischoff C. Polyneuropathien. in: Bischoff C, Dengler R, Hopf HC (ed). EMG NLG. Thieme, Stuttgart 2014; p. 154–9Google Scholar
  12. 12.
    Schulte-Mattler W. Conduction Velocity Distribution. In: Kimura J, editor. Neurophysiology of Peripheral Nerve Diseases. Amsterdam: Elsevier; 2006. p. 405–19Google Scholar
  13. 13.
    Backonja MM, Walk D, Edwards RR, Sehgal N, Moeller-Bertram T, Wasan A, Irving G, Argoff C, Wallace M. Quantitative sensory testing in measurement of neuropathic pain phenomena and other sensory abnormalities. Clin J Pain 2009; 25:641–7CrossRefGoogle Scholar
  14. 14.
    Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve 2013; 48:883–8CrossRefGoogle Scholar
  15. 15.
    Stoll G, Bendszus M, Perez J, Pham M. Magnetic resonance imaging oft her peripheral nervous system. J Neurol 2009; 256:1043–51CrossRefGoogle Scholar
  16. 16.
    Gasparotti R, Padua L, Briani C, Lauria G. New technologies for the assessment of neuropathies. Nature Reviews Neurology. 2017; 13:203–16CrossRefGoogle Scholar
  17. 17.
    Gasparotti et al. Neuroimaging in the diagnosis of atypical polyradiculopolyneuropathies: report of three cases and review of the literature. J Neurol 262:1714–23Google Scholar
  18. 18.
    Van den Bergh PY et al. European Federation of Neurological Science/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating neuropathy: report of a joint task force of the European Federation of Neurological Science and the Peripheral Nerve Society. Eur J Neurol 2010; 17:356–63CrossRefGoogle Scholar
  19. 19.
    Ellegala DB et al. Characterization of genetically defined types of Charcot-Marie-Tooth neuropathies by using magnetic resonance imaging. J Neurosurg 2005; 102:242–5CrossRefGoogle Scholar
  20. 20.
    Zaidman CM, Harms MB, Pestronk A. Ultrasound of inherited versus acquired demyelinating neuropathies. J Neurol 2013; 260:3115–21CrossRefGoogle Scholar
  21. 21.
    Grimm A et al. Ultrasound pattern sum score, homogeneity score and regional nerve enlargement index for the differentiation of demyelinating inflammatory and hereditary neuropathies. Clin Neurophysiol 2016; 127:2618–24CrossRefGoogle Scholar
  22. 22.
    Dyck PJ, Katz, KM, Karres, JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817–24CrossRefGoogle Scholar
  23. 23.
    Bulton AJ, Vinik AL, Arezzo J et al. Diabetic neuropathies a statement by the American Diabetes Association. Diabetes Care 2005; 28:956–62CrossRefGoogle Scholar
  24. 24.
    Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 2006; 63(8):1075–9CrossRefGoogle Scholar
  25. 25.
    Hanewinckel R, Drenthen J, Ligthart S, Dehghan A, Franco OH, Hofman A et al. Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study. J Neurol Neurosurg Psychiatr. 2016; 87(12):1336–42CrossRefGoogle Scholar
  26. 26.
    Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24:1448–53CrossRefGoogle Scholar
  27. 27.
    Summer CJ, Sheth S, Griffin JW, Cornblath DR, Podydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60:108–11CrossRefGoogle Scholar
  28. 28.
    Saperstein DS, Wolfe GJ, Gronseth GS et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol 2003; 60:1296–301CrossRefGoogle Scholar
  29. 29.
    Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant polyneuropathy. Arch Intern Med. 2004; 164:1296–1301Google Scholar
  30. 30.
    Callaghan BC, Price RS, Feldman EL. Diagnostic and therapeutic advances: distal symmetric polyneuropathy. JAMA 2015; 314:2172–81CrossRefGoogle Scholar
  31. 31.
    Kelly JJ, Kyle RA, O’Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31:1480–3CrossRefGoogle Scholar
  32. 32.
    Kahn SN, Bira M. Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum. Clin Chem 1988; 34:1633–5PubMedGoogle Scholar
  33. 33.
    Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn PJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2005; 615–20Google Scholar
  34. 34.
    Chaudry HM, Mauermann ML, Rajkumas SV. Monoclonal gammopathy-associated peripheral neuropathy: Diagnosis and management. Mayo Clin Proc 2017; 92:838–50CrossRefGoogle Scholar
  35. 35.
    Braathen GJ, Sand JC, Lobato A, Hoyer H, Russel MB. Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 2011; 18:39–48CrossRefGoogle Scholar
  36. 36.
    England JD, Groseth GS, Franklin G et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory genetic testing. Neurology 2009; 72:185–92CrossRefGoogle Scholar
  37. 37.
    Gallagher G, Rabquer A, Kerber K, Cabalek B, Callaghan B. Value of thyroid and rheumatologic studies in the evaluation of peripheral neuropathy. Neurology Clinical practice 2013; 3:90–8CrossRefGoogle Scholar
  38. 38.
    Van den Bergh PYK, Haddenb RDM, Bouchec P, Cornblathd DR, Hahne A, Illaf I, Koskig CL, J. Légerh JM, Nobile-Orazioi E, Pollardj J, Sommerk C, van Doornl PA, van Schaik IN. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision Members of the Task Force. Eur J Neurol 2010; 17:356–63CrossRefGoogle Scholar
  39. 39.
    Luria G. et al. European Federation of Neurological Science/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. J Periph Nerv Syst 2010; 15:79–92CrossRefGoogle Scholar
  40. 40.
    Sachedina S, Toth C. Progression in idiopathic, diabetic, paraproteinemic, alcoholic and B12 deficiency neuropathy. J Periph Nerv Syst 2013; 18:247–55CrossRefGoogle Scholar
  41. 41.
    Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol 1999; 56:540–7CrossRefGoogle Scholar
  42. 42.
    Notermans NC, Wokke HJ, van der Graaf Y, Franssen H, van Dijk GW, Jennekens FG. Chronic idiopathic axonal neuropathy: a five year follow-up. J Neurol Neurosurg Psychiat 1994; 57:1525–7CrossRefGoogle Scholar
  43. 43.
    Euerlings M, van den Berg LH, Wokke JH, Franssen H, Vrancken AF, Notermans NC. Increase of sural nerve T cells in progressive axonal neuropathy and monoclonal gammopathy. Neurology 2003; 61:707–9CrossRefGoogle Scholar
  44. 44.
    Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063. doi: 10.1002/14651858.CD002063.pub6.Google Scholar
  45. 45.
    Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017 Jan 13;1:CD010369. doi: 10.1002/14651858.CD010369.pub2Google Scholar
  46. 46.
    Finsterer J, Wanschitz J, Quasthoff S, Iglseder S, Löscher W, Grisold W. Causally treatable, hereditary neuropathies in Fabry’s disease, transthyretin-related familial amyloidosis, and Pompe’s disease. Acta Neurol Scand 2017; 136(6):558–69CrossRefGoogle Scholar
  47. 47.
    Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79:785–92CrossRefGoogle Scholar
  48. 48.
    Berk JL, Suhr OB, Obici L et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310:2658–67CrossRefGoogle Scholar
  49. 49.
    Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016 Oct 4;10:CD002827Google Scholar
  50. 50.
    Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane. Database Syst Rev 2012; 6:CD007543PubMedCentralGoogle Scholar
  51. 51.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403CrossRefGoogle Scholar
  52. 52.
    Dworkin RH, O’Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(suppl):S3–S14CrossRefGoogle Scholar
  53. 53.
    Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113–e88CrossRefGoogle Scholar
  54. 54.
    Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; 7:CD008943Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.MünchenDeutschland

Personalised recommendations